FibroBiologics, Inc. 8-K

What Happened

• On Feb. 6, 2026 FibroBiologics, Inc. (FBLG) filed an 8-K reporting that Nasdaq notified the company that its market value of listed securities (MVLS) remained below the $35 million minimum required under Nasdaq Listing Rule 5550(b)(2). Nasdaq previously notified the company on Aug. 4, 2025 and granted a 180-calendar day cure period that expired Feb. 2, 2026.
• On Feb. 3, 2026 the Listing Qualifications Staff informed the company that the MVLS deficiency, together with a previously-reported bid-price deficiency under Rule 5550(a)(2), serves as an additional basis for delisting. FibroBiologics presented a plan at a Nasdaq Hearings Panel and is awaiting the Panel’s formal decision; the shares remain listed and trading pending that decision and any extension the Panel may grant.

Key Details

• Nasdaq MVLS minimum: $35 million; company was below that threshold for the required period.
• Cure period: 180-calendar days granted under Rule 5810(c)(3)(C), which expired Feb. 2, 2026.
• Company action: Filed definitive proxy materials on Dec. 29, 2025 seeking shareholder approval of a reverse stock split between 1-for-5 and 1-for-30 (ratio to be set by the board).
• Status: Company presented its plan to regain compliance at a hearing; awaiting the Panel’s decision. Company remains listed pending the Panel’s ruling and any extension.

Why It Matters

• This filing signals a material listing risk: Nasdaq identified two listing-rule deficiencies (MVLS and bid price), and delisting could affect the stock’s liquidity, market visibility and investor access.
• Management is pursuing steps (including a possible reverse split) to regain compliance, but the filing cautions there is no assurance the Panel will grant an extension or that the measures will succeed.
• Retail investors should monitor Nasdaq’s Panel decision, any shareholder vote on the reverse split, and subsequent company filings for updates on listing status and potential impacts to trading and liquidity.